Population Based Genetic Testing For High-risk Breast And Ovarian Cancer Predisposition Genes
Funder
National Health and Medical Research Council
Funding Amount
$1,112,985.00
Summary
Inherited mutations in BRCA1 and BRCA2 confer a very high risk of breast and ovarian cancer. Importantly, once carriers are identified, effective strategies are available that can dramatically reduce the risk of cancer. We will perform genetic testing of a healthy western population to identify breast/ovarian cancer genes before the women develop cancer. Population-based screening could significantly reduce the incidence of these diseases.
A Novel Multi-gene Marker Blood Test To Increase Community Participation In Colorectal Cancer Screening.
Funder
National Health and Medical Research Council
Funding Amount
$581,116.00
Summary
Bowel cancer screening programs are vital for early detection and prevention, but participation with the traditional faecal testing mode is less than 35%. Reasons include dislike or unsuitability for faecal testing. These barriers could be overcome and participation could increase using a different sampling mode for the screening test. We have developed a blood test for bowel cancer and will investigate if people who will not screen with the stool test will screen with the blood test instead.
A Functional Assay To Classify Genetic Variants In Lynch Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$368,195.00
Summary
At least one person in every 1000 is affected by Lynch syndrome, in which faulty DNA repair machinery causes high rates of cancer. People with Lynch syndrome can have their risk of cancer cut substantially with regular screening. However, we often struggle to understand whether people with 'non-standard' DNA sequences in particular genes actually have Lynch syndrome. This project develops a simple test that will tell clinicians whether a given sequence change relates to Lynch syndrome or not.
Genome Engineered, Preclinical Models Of Serrated Colorectal Cancer To Fast-track A High Sensitivity, Early Detection Test
Funder
National Health and Medical Research Council
Funding Amount
$593,854.00
Summary
1 in 12 Australians will develop colorectal cancer. Here we use information about changes to the genetic (inherited) material of these cancers to develop new, complex models of this disease. This teaches us about what those changes do, and highlights important targets for future drug therapies. We are also developing a better test to detect hidden pre-cancers that are not well detected by our current population screening strategy, to help reduce deaths from this disease.
The CRISP Trial: An RCT Of Risk Assessment And Decision Support To Implement Risk-stratified Colorectal Cancer Screening In Primary Care.
Funder
National Health and Medical Research Council
Funding Amount
$936,641.00
Summary
There is a mismatch between people’s use of bowel cancer screening tests through faecal occult blood testing or colonoscopy and their individual risk of bowel cancer. Building on the work of our NHMRC Centre for Research Excellence (CRE) on Optimising Colorectal Cancer Screening, this trial will test the effect of an electronic risk assessment tool, implemented in general practice, on use of the most appropriate screening test for bowel cancer based on a person’s risk of developing the condition
Circulating Tumour DNA (ctDNA) As A Diagnostic Tool In Colorectal Cancer: Role In Screening And Early Detection Of Metastatic Or Recurrent Disease
Funder
National Health and Medical Research Council
Funding Amount
$500,478.00
Summary
These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to ....These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to save lives, will be greatly increased.Read moreRead less
Risks And Benefits Of Breast Cancer Screening: BreastScreen WA Cohort Study Of Overdiagnosis And Breast Cancer Mortality
Funder
National Health and Medical Research Council
Funding Amount
$201,524.00
Summary
Overdiagnosis is the major downside of screening for breast cancer. This occurs when screening detects cancers that would not have caused symptoms in the woman's lifetime. This study aims to quantify the amount of overdiagnosis that occurs in the Australian breast cancer screening program (BreastScreen)
Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
About 14,000 cases of bowel cancer occur annually in Australia despite the availability of life-saving screening. Most people do not receive recommended screening colonoscopy. We will look at why people at high-risk avoid screening and why people at average risk seek unnecessary screening. We will analyse family history and contacts with the healthcare system that impact screening decisions. We will determine the impact of screening on reducing the number of new cases and deaths.
Identification Of Novel Genes Predisposing To Male Breast Cancer, Their Prevalence And Associated Cancer Risks.
Funder
National Health and Medical Research Council
Funding Amount
$210,284.00
Summary
Male breast cancer (MBC) is rare and understudied. Using the latest technology, this study will identify new genes which cause familial MBC to aid in the genetic counselling and risk assessment of an affected man and his family. The frequency of these novel genes, and all known breast cancer genes will be assessed in a second group of affected men as well as families with an increased female breast cancer risk. By better understanding the cause of MBC, we can improve its management.